BofA全球研究近日宣布，正式启动对生物制药公司Inhibikase Therapeutics, Inc.的股票研究覆盖，并首次给予"买入"评级。该机构为Inhibikase Therapeutics设定了6美元的目标股价。
此次覆盖启动表明，机构投资者对该公司的发展前景持乐观态度。"买入"评级通常意味着分析师预期该股票在未来一段时间内将有优于市场平均水平的表现。
BofA全球研究近日宣布，正式启动对生物制药公司Inhibikase Therapeutics, Inc.的股票研究覆盖，并首次给予"买入"评级。该机构为Inhibikase Therapeutics设定了6美元的目标股价。
此次覆盖启动表明，机构投资者对该公司的发展前景持乐观态度。"买入"评级通常意味着分析师预期该股票在未来一段时间内将有优于市场平均水平的表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.